EXACT SCIENCES CORP (EXAS) Stock Fundamental Analysis

NASDAQ:EXAS • US30063P1057

103.24 USD
+0.01 (+0.01%)
At close: Feb 13, 2026
103.14 USD
-0.1 (-0.1%)
After Hours: 2/13/2026, 8:05:50 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to EXAS. EXAS was compared to 523 industry peers in the Biotechnology industry. The financial health of EXAS is average, but there are quite some concerns on its profitability. EXAS has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • EXAS had negative earnings in the past year.
  • EXAS had a positive operating cash flow in the past year.
  • In the past 5 years EXAS always reported negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: EXAS reported negative operating cash flow in multiple years.
EXAS Yearly Net Income VS EBIT VS OCF VS FCFEXAS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M -800M -1B

1.2 Ratios

  • Looking at the Return On Assets, with a value of -16.72%, EXAS is in the better half of the industry, outperforming 78.39% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -39.44%, EXAS is in the better half of the industry, outperforming 71.32% of the companies in the same industry.
Industry RankSector Rank
ROA -16.72%
ROE -39.44%
ROIC N/A
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
EXAS Yearly ROA, ROE, ROICEXAS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

  • EXAS has a better Gross Margin (67.37%) than 80.50% of its industry peers.
  • EXAS's Gross Margin has declined in the last couple of years.
  • EXAS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
EXAS Yearly Profit, Operating, Gross MarginsEXAS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, EXAS has more shares outstanding
  • EXAS has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for EXAS is higher compared to a year ago.
EXAS Yearly Shares OutstandingEXAS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
EXAS Yearly Total Debt VS Total AssetsEXAS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 3.00 indicates that EXAS is not in any danger for bankruptcy at the moment.
  • EXAS's Altman-Z score of 3.00 is fine compared to the rest of the industry. EXAS outperforms 68.45% of its industry peers.
  • EXAS has a debt to FCF ratio of 9.47. This is a negative value and a sign of low solvency as EXAS would need 9.47 years to pay back of all of its debts.
  • EXAS's Debt to FCF ratio of 9.47 is amongst the best of the industry. EXAS outperforms 90.82% of its industry peers.
  • EXAS has a Debt/Equity ratio of 0.93. This is a neutral value indicating EXAS is somewhat dependend on debt financing.
  • EXAS has a worse Debt to Equity ratio (0.93) than 74.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.93
Debt/FCF 9.47
Altman-Z 3
ROIC/WACCN/A
WACC11.7%
EXAS Yearly LT Debt VS Equity VS FCFEXAS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 2.72 indicates that EXAS has no problem at all paying its short term obligations.
  • EXAS has a Current ratio of 2.72. This is in the lower half of the industry: EXAS underperforms 68.07% of its industry peers.
  • EXAS has a Quick Ratio of 2.44. This indicates that EXAS is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of EXAS (2.44) is worse than 69.22% of its industry peers.
Industry RankSector Rank
Current Ratio 2.72
Quick Ratio 2.44
EXAS Yearly Current Assets VS Current LiabilitesEXAS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The earnings per share for EXAS have decreased strongly by -354.70% in the last year.
  • Looking at the last year, EXAS shows a quite strong growth in Revenue. The Revenue has grown by 14.47% in the last year.
  • EXAS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 25.78% yearly.
EPS 1Y (TTM)-354.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.38%
Revenue 1Y (TTM)14.47%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%20.05%

3.2 Future

  • Based on estimates for the next years, EXAS will show a very strong growth in Earnings Per Share. The EPS will grow by 21.50% on average per year.
  • EXAS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.01% yearly.
EPS Next Y86.63%
EPS Next 2Y43.53%
EPS Next 3Y30.61%
EPS Next 5Y21.5%
Revenue Next Year17.56%
Revenue Next 2Y15.53%
Revenue Next 3Y14.5%
Revenue Next 5Y11.01%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
EXAS Yearly Revenue VS EstimatesEXAS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
EXAS Yearly EPS VS EstimatesEXAS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • EXAS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • With a Price/Forward Earnings ratio of 308.58, EXAS can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of EXAS indicates a rather cheap valuation: EXAS is cheaper than 87.38% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.96, EXAS is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 308.58
EXAS Price Earnings VS Forward Price EarningsEXAS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200 300

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, EXAS is valued cheaply inside the industry as 89.10% of the companies are valued more expensively.
  • EXAS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. EXAS is cheaper than 92.16% of the companies in the same industry.
Industry RankSector Rank
P/FCF 79.29
EV/EBITDA 327.32
EXAS Per share dataEXAS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • EXAS's earnings are expected to grow with 30.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.53%
EPS Next 3Y30.61%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • EXAS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EXACT SCIENCES CORP

NASDAQ:EXAS (2/13/2026, 8:05:50 PM)

After market: 103.14 -0.1 (-0.1%)

103.24

+0.01 (+0.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03
Earnings (Next)02-24
Inst Owners94.41%
Inst Owner Change-1.09%
Ins Owners0.85%
Ins Owner Change-0.36%
Market Cap19.70B
Revenue(TTM)3.08B
Net Income(TTM)-986.58M
Analysts66.9
Price Target103.87 (0.61%)
Short Float %4.04%
Short Ratio1.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)27.24%
Min EPS beat(2)-40.06%
Max EPS beat(2)94.53%
EPS beat(4)1
Avg EPS beat(4)-344.13%
Min EPS beat(4)-1391.93%
Max EPS beat(4)94.53%
EPS beat(8)4
Avg EPS beat(8)-160.89%
EPS beat(12)8
Avg EPS beat(12)-92.72%
EPS beat(16)11
Avg EPS beat(16)-67.39%
Revenue beat(2)2
Avg Revenue beat(2)2.8%
Min Revenue beat(2)2.65%
Max Revenue beat(2)2.95%
Revenue beat(4)3
Avg Revenue beat(4)1.49%
Min Revenue beat(4)-0.27%
Max Revenue beat(4)2.95%
Revenue beat(8)3
Avg Revenue beat(8)0.13%
Revenue beat(12)6
Avg Revenue beat(12)1.15%
Revenue beat(16)10
Avg Revenue beat(16)1.59%
PT rev (1m)3.2%
PT rev (3m)45.86%
EPS NQ rev (1m)2.26%
EPS NQ rev (3m)-1225%
EPS NY rev (1m)-3.55%
EPS NY rev (3m)-15.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 308.58
P/S 6.36
P/FCF 79.29
P/OCF 50.65
P/B 7.83
P/tB N/A
EV/EBITDA 327.32
EPS(TTM)-5.32
EYN/A
EPS(NY)0.33
Fwd EY0.32%
FCF(TTM)1.3
FCFY1.26%
OCF(TTM)2.04
OCFY1.97%
SpS16.24
BVpS13.18
TBVpS-4.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -16.72%
ROE -39.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.37%
FCFM 8.02%
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
F-Score4
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0.93
Debt/FCF 9.47
Debt/EBITDA 36.88
Cap/Depr 63.99%
Cap/Sales 4.53%
Interest Coverage N/A
Cash Conversion 611.3%
Profit Quality N/A
Current Ratio 2.72
Quick Ratio 2.44
Altman-Z 3
F-Score4
WACC11.7%
ROIC/WACCN/A
Cap/Depr(3y)84.38%
Cap/Depr(5y)130.41%
Cap/Sales(3y)7.28%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-354.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.38%
EPS Next Y86.63%
EPS Next 2Y43.53%
EPS Next 3Y30.61%
EPS Next 5Y21.5%
Revenue 1Y (TTM)14.47%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%20.05%
Revenue Next Year17.56%
Revenue Next 2Y15.53%
Revenue Next 3Y14.5%
Revenue Next 5Y11.01%
EBIT growth 1Y25.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year324.81%
EBIT Next 3Y83.49%
EBIT Next 5Y52.7%
FCF growth 1Y1146.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y179.09%
OCF growth 3YN/A
OCF growth 5YN/A

EXACT SCIENCES CORP / EXAS FAQ

What is the fundamental rating for EXAS stock?

ChartMill assigns a fundamental rating of 4 / 10 to EXAS.


What is the valuation status of EXACT SCIENCES CORP (EXAS) stock?

ChartMill assigns a valuation rating of 4 / 10 to EXACT SCIENCES CORP (EXAS). This can be considered as Fairly Valued.


How profitable is EXACT SCIENCES CORP (EXAS) stock?

EXACT SCIENCES CORP (EXAS) has a profitability rating of 2 / 10.


What is the earnings growth outlook for EXACT SCIENCES CORP?

The Earnings per Share (EPS) of EXACT SCIENCES CORP (EXAS) is expected to grow by 86.63% in the next year.